Supernus Pharmaceuticals
SUPN
64 hedge funds and large institutions have $234M invested in Supernus Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 25 increasing their positions, 14 reducing their positions, and 6 closing their positions.
117% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 6
79% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 14
25% more capital invested
Capital invested by funds: $187M → $234M (+$47M)
12% more funds holding
Funds holding: 57 → 64 (+7)
9% more call options, than puts
Call options by funds: $2.48M | Put options by funds: $2.27M
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
+$9.86M |
| 2 |
OHCM
Orchard Hill Capital Management
New York
|
+$9.68M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$8.27M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.76M |
| 5 |
MOACM
Mutual of America Capital Management
New York
|
+$2.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$991K |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$733K |
| 3 |
Millennium Management
New York
|
-$633K |
| 4 |
O
OrbiMed
New York
|
-$415K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$363K |
SUPN Hedge Fund Activity: Q4 2013 in Review
64 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q4 2013, worth a combined $234M — up 25% from $187M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new SUPN positions and 6 closed out — a net gain of 7 holders — while 25 added to existing stakes and 14 trimmed.
The largest buyer was Ardsley Advisory Partners, opening a new position worth an estimated $9.86M. The largest seller was T. Rowe Price Associates, cutting an estimated $991K.
- 64 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q4 2013, up from 57 in Q3 2013.
- Funds reported $234M of Supernus Pharmaceuticals stock for Q4 2013, up 25% quarter-over-quarter.
- 13 funds opened new Supernus Pharmaceuticals positions in Q4 2013 and 6 closed out, a net change of +7 holders.
- The largest Supernus Pharmaceuticals buyer in Q4 2013 was Ardsley Advisory Partners, an estimated $9.86M added.
- The largest Supernus Pharmaceuticals seller in Q4 2013 was T. Rowe Price Associates, an estimated $991K sold.
Based on aggregated 13F filings for Q4 2013.